Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E. Rodenhuis S, et al. Among authors: peterse jl. Lancet. 1998 Aug 15;352(9127):515-21. doi: 10.1016/S0140-6736(98)01350-6. Lancet. 1998. PMID: 9716055 Clinical Trial.
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.
Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, van de Vijver MJ, Dalesio O, van Tinteren H, Rutgers EJ, Richelt DJ, Rodenhuis S. Schrama JG, et al. Among authors: peterse jl. Ann Oncol. 2002 May;13(5):689-98. doi: 10.1093/annonc/mdf203. Ann Oncol. 2002. PMID: 12075736 Free article. Clinical Trial.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Bueno-de-Mesquita JM, et al. Among authors: peterse jl. Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Lancet Oncol. 2007. PMID: 18042430
A gene-expression signature as a predictor of survival in breast cancer.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. van de Vijver MJ, et al. Among authors: peterse jl. N Engl J Med. 2002 Dec 19;347(25):1999-2009. doi: 10.1056/NEJMoa021967. N Engl J Med. 2002. PMID: 12490681 Free article.
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.
Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, Bontenbal M, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Ten Vergert EM, de Vries EG, Rodenhuis S, van de Vijver MJ. Faneyte IF, et al. Among authors: peterse jl. Clin Cancer Res. 2004 Jul 1;10(13):4457-63. doi: 10.1158/1078-0432.CCR-03-0054. Clin Cancer Res. 2004. PMID: 15240537 Clinical Trial.
169 results